Cargando…
Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications
BACKGROUND: No residual disease (CC 0) following cytoreductive surgery is pivotal for the prognosis of women with advanced stage epithelial ovarian cancer (EOC). Improving CC 0 resection rates without increasing morbidity and no delay in subsequent chemotherapy favors a better outcome in these women...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638711/ https://www.ncbi.nlm.nih.gov/pubmed/37951927 http://dx.doi.org/10.1186/s13048-023-01303-1 |
_version_ | 1785133653475459072 |
---|---|
author | de Jong, Diederick Thangavelu, Amudha Broadhead, Timothy Chen, Inga Burke, Dermot Hutson, Richard Johnson, Racheal Kaufmann, Angelika Lodge, Peter Nugent, David Quyn, Aaron Theophilou, Georgios Laios, Alexandros |
author_facet | de Jong, Diederick Thangavelu, Amudha Broadhead, Timothy Chen, Inga Burke, Dermot Hutson, Richard Johnson, Racheal Kaufmann, Angelika Lodge, Peter Nugent, David Quyn, Aaron Theophilou, Georgios Laios, Alexandros |
author_sort | de Jong, Diederick |
collection | PubMed |
description | BACKGROUND: No residual disease (CC 0) following cytoreductive surgery is pivotal for the prognosis of women with advanced stage epithelial ovarian cancer (EOC). Improving CC 0 resection rates without increasing morbidity and no delay in subsequent chemotherapy favors a better outcome in these women. Prerequisites to facilitate this surgical paradigm shift and subsequent ramifications need to be addressed. This quality improvement study assessed 559 women with advanced EOC who had cytoreductive surgery between January 2014 and December 2019 in our tertiary referral centre. Following implementation of the Enhanced Recovery After Surgery (ERAS) pathway and prehabilitation protocols, the surgical management paradigm in advanced EOC patients shifted towards maximal surgical effort cytoreduction in 2016. Surgical outcome parameters before, during, and after this paradigm shift were compared. The primary outcome measure was residual disease (RD). The secondary outcome parameters were postoperative morbidity, operative time (OT), length of stay (LOS) and progression-free-survival (PFS). RESULTS: R0 resection rate in patients with advanced EOC increased from 57.3% to 74.4% after the paradigm shift in surgical management whilst peri-operative morbidity and delays in adjuvant chemotherapy were unchanged. The mean OT increased from 133 + 55 min to 197 + 85 min, and postoperative high dependency/intensive care unit (HDU/ICU) admissions increased from 8.1% to 33.1%. The subsequent mean LOS increased from 7.0 + 2.6 to 8.4 + 4.9 days. The median PFS was 33 months. There was no difference for PFS in the three time frames but a trend towards improvement was observed. CONCLUSIONS: Improved CC 0 surgical cytoreduction rates without compromising morbidity in advanced EOC is achievable owing to the right conditions. Maximal effort cytoreductive surgery should solely be carried out in high output tertiary referral centres due to the associated substantial prerequisites and ramifications. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13048-023-01303-1. |
format | Online Article Text |
id | pubmed-10638711 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-106387112023-11-11 Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications de Jong, Diederick Thangavelu, Amudha Broadhead, Timothy Chen, Inga Burke, Dermot Hutson, Richard Johnson, Racheal Kaufmann, Angelika Lodge, Peter Nugent, David Quyn, Aaron Theophilou, Georgios Laios, Alexandros J Ovarian Res Research BACKGROUND: No residual disease (CC 0) following cytoreductive surgery is pivotal for the prognosis of women with advanced stage epithelial ovarian cancer (EOC). Improving CC 0 resection rates without increasing morbidity and no delay in subsequent chemotherapy favors a better outcome in these women. Prerequisites to facilitate this surgical paradigm shift and subsequent ramifications need to be addressed. This quality improvement study assessed 559 women with advanced EOC who had cytoreductive surgery between January 2014 and December 2019 in our tertiary referral centre. Following implementation of the Enhanced Recovery After Surgery (ERAS) pathway and prehabilitation protocols, the surgical management paradigm in advanced EOC patients shifted towards maximal surgical effort cytoreduction in 2016. Surgical outcome parameters before, during, and after this paradigm shift were compared. The primary outcome measure was residual disease (RD). The secondary outcome parameters were postoperative morbidity, operative time (OT), length of stay (LOS) and progression-free-survival (PFS). RESULTS: R0 resection rate in patients with advanced EOC increased from 57.3% to 74.4% after the paradigm shift in surgical management whilst peri-operative morbidity and delays in adjuvant chemotherapy were unchanged. The mean OT increased from 133 + 55 min to 197 + 85 min, and postoperative high dependency/intensive care unit (HDU/ICU) admissions increased from 8.1% to 33.1%. The subsequent mean LOS increased from 7.0 + 2.6 to 8.4 + 4.9 days. The median PFS was 33 months. There was no difference for PFS in the three time frames but a trend towards improvement was observed. CONCLUSIONS: Improved CC 0 surgical cytoreduction rates without compromising morbidity in advanced EOC is achievable owing to the right conditions. Maximal effort cytoreductive surgery should solely be carried out in high output tertiary referral centres due to the associated substantial prerequisites and ramifications. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13048-023-01303-1. BioMed Central 2023-11-11 /pmc/articles/PMC10638711/ /pubmed/37951927 http://dx.doi.org/10.1186/s13048-023-01303-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research de Jong, Diederick Thangavelu, Amudha Broadhead, Timothy Chen, Inga Burke, Dermot Hutson, Richard Johnson, Racheal Kaufmann, Angelika Lodge, Peter Nugent, David Quyn, Aaron Theophilou, Georgios Laios, Alexandros Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications |
title | Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications |
title_full | Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications |
title_fullStr | Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications |
title_full_unstemmed | Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications |
title_short | Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications |
title_sort | prerequisites to improve surgical cytoreduction in figo stage iii/iv epithelial ovarian cancer and subsequent clinical ramifications |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638711/ https://www.ncbi.nlm.nih.gov/pubmed/37951927 http://dx.doi.org/10.1186/s13048-023-01303-1 |
work_keys_str_mv | AT dejongdiederick prerequisitestoimprovesurgicalcytoreductioninfigostageiiiivepithelialovariancancerandsubsequentclinicalramifications AT thangaveluamudha prerequisitestoimprovesurgicalcytoreductioninfigostageiiiivepithelialovariancancerandsubsequentclinicalramifications AT broadheadtimothy prerequisitestoimprovesurgicalcytoreductioninfigostageiiiivepithelialovariancancerandsubsequentclinicalramifications AT cheninga prerequisitestoimprovesurgicalcytoreductioninfigostageiiiivepithelialovariancancerandsubsequentclinicalramifications AT burkedermot prerequisitestoimprovesurgicalcytoreductioninfigostageiiiivepithelialovariancancerandsubsequentclinicalramifications AT hutsonrichard prerequisitestoimprovesurgicalcytoreductioninfigostageiiiivepithelialovariancancerandsubsequentclinicalramifications AT johnsonracheal prerequisitestoimprovesurgicalcytoreductioninfigostageiiiivepithelialovariancancerandsubsequentclinicalramifications AT kaufmannangelika prerequisitestoimprovesurgicalcytoreductioninfigostageiiiivepithelialovariancancerandsubsequentclinicalramifications AT lodgepeter prerequisitestoimprovesurgicalcytoreductioninfigostageiiiivepithelialovariancancerandsubsequentclinicalramifications AT nugentdavid prerequisitestoimprovesurgicalcytoreductioninfigostageiiiivepithelialovariancancerandsubsequentclinicalramifications AT quynaaron prerequisitestoimprovesurgicalcytoreductioninfigostageiiiivepithelialovariancancerandsubsequentclinicalramifications AT theophilougeorgios prerequisitestoimprovesurgicalcytoreductioninfigostageiiiivepithelialovariancancerandsubsequentclinicalramifications AT laiosalexandros prerequisitestoimprovesurgicalcytoreductioninfigostageiiiivepithelialovariancancerandsubsequentclinicalramifications |